KOTOLOVÁ, Hana, Martina NOVÁKOVÁ, Eliška NOVÁKOVÁ, Tomáš HAMMER and Libor USTOHAL. CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC. In ESCP PRAGUE SYMPOSIUM 2022. 2022. Available from: https://dx.doi.org/10.1007/s11096-022-01521-5.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC
Name (in English) CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC
Authors KOTOLOVÁ, Hana, Martina NOVÁKOVÁ, Eliška NOVÁKOVÁ, Tomáš HAMMER and Libor USTOHAL.
Edition ESCP PRAGUE SYMPOSIUM 2022, 2022.
Other information
Type of outcome Conference abstract
Confidentiality degree is not subject to a state or trade secret
WWW 50th ESCP Symposium on Clinical Pharmacy, Polypharmacy and ageing - highly individualized, interprofessional, person-centered care. Int J Clin Pharm 44, 1464–1566 (2022). https://doi.org/10.1007/s11096-022-01521-5
Organization unit Faculty of Pharmacy
Doi http://dx.doi.org/10.1007/s11096-022-01521-5
Keywords in English Clozapine, augmentation, long-acting injectable antipsychotics
Tags International impact
Changed by Changed by: JUDr. Sabina Krejčiříková, učo 383857. Changed: 10/5/2023 15:59.
Abstract
Clozapine is the drug of choice for drug-resistant schizophrenia, in which a combination of two antipsychotics with different mechanisms of action had no therapeutic effect. However, many patients have a continuing lack of response to treatment, so clozapine is combined with other psychotropic drugs. In the case of a clozapine-resistant patient who is in addition nonadherent to therapy, augmentation of clozapine with long-acting injectable antipsychotics (LAI APs) is offered. This combination is not yet widely used due to the possible occurrence of side effects (blood dyscrasias, weight gain, hyperglycemia, etc.). Experience with the combination of clozapine and LAI APs suggests that patients who are nonadherent and resistant to clozapine therapy could benefit from this treatment, although the amount of clinical data is currently low. Therefore, augmentation of clozapine with LAI APs should be individualized, based on sufficient medical experience.
PrintDisplayed: 29/7/2024 09:24